Literature DB >> 16425303

Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma.

Fernanda Roca1, Laura V Mauro, Ana Morandi, Fernando Bonadeo, Carlos Vaccaro, Guillermo Ojea Quintana, Sergio Specterman, Elisa Bal de Kier Joffé, María Guadalupe Pallotta, Lydia Inés Puricelli, José Lastiri.   

Abstract

BACKGROUND AND OBJECTIVES: Therapy of colorectal tumors (CRC) based on histology and clinical factors is insufficient to predict the evolution of each patient. The finding of molecular abnormalities able to differentiate subgroups of patients with bad prognosis will improve our ability to treat them successfully. Our purpose was to analyze retrospectively the prognostic input of E-cadherin, beta-catenin, metalloproteinases (MMPs) (7 and 9), and tissue inhibitors of metalloproteinases (TIMPs) (1 and 2) in patients with a follow-up period of 5 years.
METHODS: Antigen expression was analyzed by immunohistochemistry. Prognostic evaluation was performed with the multivariate proportional hazards model.
RESULTS: We demonstrated a concomitant loss of E-cadherin and beta-catenin at membranous level and an abnormal accumulation of nuclear beta-catenin. Besides, we found that all MMPs and TIMPs studied were overexpressed in CRC tissue. There was no association between the expression of any of these molecules and the known clinical-pathological parameters employed in CRC pathology. A multivariate analysis demonstrated that the overall survival could be independently predicted by the loss of E-cadherin and the overexpression of TIMP-2.
CONCLUSIONS: The expression of E-cadherin and TIMP-2 could be relevant in determining the prognosis of CRC patients and providing a more accurate mechanism for their classification. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16425303     DOI: 10.1002/jso.20413

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  26 in total

Review 1.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

Review 2.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

3.  Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis.

Authors:  Haiyan Chen; Yeting Hu; Weibo Xiang; Yibo Cai; Zhanhuai Wang; Qian Xiao; Yue Liu; Qiong Li; Kefeng Ding
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Prognostic implications of adhesion molecule expression in colorectal cancer.

Authors:  Kyung-Jin Seo; Maru Kim; Jeana Kim
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 5.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.

Authors:  Jolana Turecková; Martina Vojtechová; Michaela Krausová; Eva Sloncová; Vladimír Korínek
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

7.  The Prognostic Impact of Protein Expression of E-Cadherin-Catenin Complexes Differs between Rectal and Colon Carcinoma.

Authors:  Rolf Aamodt; Johan Bondi; Solveig Norheim Andersen; Arne Bakka; Geir Bukholm; Ida R K Bukholm
Journal:  Gastroenterol Res Pract       Date:  2010-08-16       Impact factor: 2.260

Review 8.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04

9.  Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy.

Authors:  Lukáš Krbal; Veronika Hanušová; Jiří Soukup; Stanislav John; Petra Matoušková; Aleš Ryška
Journal:  Tumour Biol       Date:  2016-01-21

10.  Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma.

Authors:  Adam Elzagheid; Abdelbaset Buhmeida; Eija Korkeila; Yrjo Collan; Kari Syrjanen; Seppo Pyrhonen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.